Continuing Medical Education
Cleveland Clinic Center for Continuing Education
The Center for Continuing Education is committed to sharing a wealth of knowledge with physicians, nurses, and other medical professionals worldwide for more than 80 years. Its objective is to provide high-quality, innovative educational programs that increase the knowledge of health care providers, resulting in improved patient outcomes.
American Society of Clinical Oncology (ASCO)
Featured Abstracts from the 2024 Annual Meeting
- "Must See" Abstracts at the 2024 ASCO Annual Meeting
- CAR T-Cell Treatment Offers Hope for Richter Transformation
- Researchers Identify Tumor Microbiome Differences in Early-vs. Average Onset Pancreatic Adenocarcinoma
- Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib
- Researchers Explore Prognostic Value of Transcriptomic Data in Multiple Myeloma
American Society for Radiation Oncology (ASTRO)
Featured Abstracts from the 2024 Annual Meeting
- ASTRO 2024 Highlights
- New Study Supports SBRT as Safe, Effective for Osteosarcoma
- One-Time Screening for Nasopharyngeal Cancer Among High-Risk Populations in the U.S. May Reduce Cancer Mortality
- Partial Breast Irradiation Delivered Daily Well Tolerated in Patients with Early-Stage Breast Cancer
- When to Pursue More Aggressive Treatment for Patients with T1-2a Cutaneous Squamous Cell Carcinoma
- Five Years of Parallel Prospective Plan of Care Reviews
American Society of Hematology (ASH)
Featured Abstracts from the 2024 Annual Meeting
- Looking Forward: Advances and Obstacles in Blood Cancer Treatment
- Major Study Finds CAR T-Cell Therapy Safe and Effective for Older Patients With B-Cell Acute Lymphoblastic Leukemia
- Access Barriers to Transplant Affect Outcomes in AML
- Real-World Study Examines Optimal Sequencing and Timing of Treatments for Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody Glofitamab Combination with Chemoimmunotherapy Safe and Effective for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
- Efficacy and Safety Outcomes of Bispecific Antibodies
